Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Expected to Post Earnings of -$0.09 Per Share

Share on StockTwits

Wall Street analysts predict that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will announce ($0.09) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.09). Sunesis Pharmaceuticals reported earnings of ($0.18) per share during the same quarter last year, which indicates a positive year over year growth rate of 50%. The firm is scheduled to report its next earnings report on Monday, November 4th.

On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.42) to ($0.37). For the next financial year, analysts forecast that the firm will report earnings of ($0.25) per share, with EPS estimates ranging from ($0.61) to $0.48. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01.

A number of equities analysts have issued reports on the stock. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright restated a “hold” rating and set a $1.50 target price on shares of Sunesis Pharmaceuticals in a research report on Friday, August 9th. Cowen restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Sunday, June 16th. Finally, Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Wednesday, May 15th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $2.92.

SNSS stock traded up $0.02 during trading on Thursday, reaching $0.80. 46,042 shares of the company were exchanged, compared to its average volume of 630,979. The stock has a market cap of $57.03 million, a P/E ratio of -1.04 and a beta of 2.79. Sunesis Pharmaceuticals has a 52-week low of $0.20 and a 52-week high of $2.26. The firm’s 50 day moving average is $0.77. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.12.

In related news, major shareholder Aisling Capital Iv, Lp bought 2,500,000 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was purchased at an average cost of $0.60 per share, for a total transaction of $1,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.22% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the business. Algert Global LLC acquired a new stake in shares of Sunesis Pharmaceuticals in the 1st quarter valued at $25,000. Fosun International Ltd purchased a new stake in shares of Sunesis Pharmaceuticals in the first quarter valued at about $863,000. Aisling Capital Management LP boosted its holdings in shares of Sunesis Pharmaceuticals by 192.3% in the first quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock valued at $9,234,000 after acquiring an additional 5,000,000 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sunesis Pharmaceuticals by 42.7% in the second quarter. Wells Fargo & Company MN now owns 1,341,151 shares of the biopharmaceutical company’s stock valued at $975,000 after acquiring an additional 401,193 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Sunesis Pharmaceuticals by 54.8% in the second quarter. Northern Trust Corp now owns 165,769 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 58,653 shares in the last quarter. 43.63% of the stock is currently owned by institutional investors.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Featured Story: What are the benefits of buying treasury bonds?

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.